American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

TreeTopp: Randomized Phase 2 Study of Varlitinib plus Capecitabine versus Placebo in Second-Line Advanced or Metastatic BTC

ASCO 2020 – Cholangiocarcinoma

Varlitinib plus capecitabine was compared with capecitabine plus placebo as second-line treatment in patients with advanced or metastatic biliary tract cancer. Read More ›

Primary Tumor versus Metastatic Tumor Tissue versus Liquid Biopsy in iCCA: A Comparative Comprehensive Genomic Profiling Study

ASCO 2020 – Cholangiocarcinoma

Liquid biopsies may offer the opportunity to obtain information regarding specific genetic mutations in intrahepatic cholangiocarcinoma. Read More ›

Clinical Activity of the RET Inhibitor Pralsetinib (BLU-667) in Patients with RET-Altered Solid Tumors

ASCO 2020 – Wrap Up

Results from the ARROW study show that pralsetinib demonstrates broad and durable antitumor activity across multiple advanced solid tumor types, regardless of RET fusion genotype. Read More ›

IDH1 Mutation Detection in ctDNA and Association with Clinical Response in Patients with Advanced iCCA from Phase 3 ClarIDHy

ASCO 2020 – Cholangiocarcinoma

Detection of IDH1 mutations in plasma from patients with intrahepatic cholangiocarcinoma is highly concordant with detection in tumor tissue. Read More ›

AcceleRET Lung: A Phase 3 Study of Pralsetinib in Patients with RET Fusion–Positive Metastatic NSCLC

ASCO 2020 – Wrap Up

The AcceleRET Lung study will evaluate the efficacy and safety of pralsetinib compared with standard of care for first-line treatment of patients with advanced/metastatic RET fusion–positive non–small-cell lung cancer. Read More ›

Efficacy of Capmatinib in Second-Line Treatment of Patients with METex14-Mutated NSCLC

ASCO 2020 – Wrap Up

Results from the phase 2 GEOMETRY mono-1 study confirm capmatinib to be efficacious in second-line treatment of patients with MET exon 14–mutated non–small-cell lung cancer. Read More ›

Efficacy and Safety of Entrectinib in Patients with NTRK Fusion–Positive Solid Tumors

ASCO 2020 – Wrap Up

An updated analysis of 3 phase 1/2 trials finds that entrectinib continues to demonstrate clinically meaningful responses in patients with NTRK fusion–positive solid tumors, including those with and without baseline central nervous system disease. Read More ›

Next-Generation RET Inhibitor TPX-0046 Is Active in Drug-Resistant and Naïve RET-Driven Cancer Models

ASCO 2020 – Wrap Up

The next-generation RET inhibitor TPX-0046 demonstrates potent in vitro and in vivo activity against a diverse range of RET alterations, including solvent front mutation–mediated resistance. Read More ›

Antitumor Activity of Selpercatinib (LOXO-292) in Patients with RET-Mutant Medullary Thyroid Cancer

ASCO 2020 – Wrap Up

Selpercatinib (LOXO-292) use was associated with durable antitumor activity in patients with RET-mutant medullary thyroid cancer previously treated with cabozantinib and/or vandetanib as well as in cabozantinib/vandetanib-naïve patients. Read More ›

Liquid Biopsy Compared with Tissue Biopsy for Molecular Profiling in Patients with NSCLC

ASCO 2020 – Wrap Up

In newly diagnosed patients with lung cancer, liquid biopsy using the Guardant 360 assay identifies actionable targets beyond those identified by tumor tissue profiling alone and with a shorter turnaround time. Read More ›

American Society of Clinical Oncology (ASCO)

Page 8 of 29